#ASH17: Seattle Genetics CEO Clay Siegall has an answer for the skeptics doubting Adcetris data for Hodgkin lymphoma
Seattle Genetics $SGEN CEO Clay Siegall ran into a wall of skepticism last summer when he rolled out positive data from their Phase III study of a new cocktail for frontline Hodgkin lymphoma. Dropping the toxic bleomycin from the standard chemo combo used to treat the disease, researchers for the biotech — partnered with Takeda — had come up with a lean but significant 5-point PFS advantage for the company’s flagship therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.